A phase 1 study to evaluate the safety and LDL cholesterol–lowering effects of RG7652, a fully human monoclonal antibody against proprotein convertase subtilisin/kexin type 9

BACKGROUND: Proprotein convertase subtilisin/kexin type 9 (PCSK9) downregulates low‐density lipoprotein (LDL) receptors, thereby leading to a rise in circulating LDL cholesterol (LDL‐C). RG7652 is a fully human monoclonal antibody against PCSK9. This placebo‐controlled, phase 1 ascending‐dose study...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cardiol
Main Authors: Baruch, Amos, Luca, Diana, Kahn, Robert S., Cowan, Kyra J., Leabman, Maya, Budha, Nageshwar R., Chiu, Cecilia P.C., Wu, Yan, Kirchhofer, Daniel, Peterson, Andrew, Davis Jr, John C., Tingley, Whittemore G.
Formato: Artigo
Idioma:Inglês
Publicado em: Wiley Periodicals, Inc. 2017
Assuntos:
Clinical Investigations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6490403/
https://ncbi.nlm.nih.gov/pubmed/28326559
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/clc.22687
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados